Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …

Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a subset …

Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis
of this variability remains poorly understood. We performed prospective targeted sequencing …

Importance The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is
approved by the US Food and Drug Administration for the treatment of microsatellite instability–…

PURPOSE Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing
has traditionally been performed in patients with colorectal (CRC) and endometrial cancer (…

Importance Treatment of locally advanced rectal (LARC) cancer involves chemoradiation,
surgery, and chemotherapy. The concept of total neoadjuvant therapy (TNT), in which …

Importance Guidelines for cancer genetic testing based on family history may miss clinically
actionable genetic changes with established implications for cancer screening or prevention…

Ploidy abnormalities are a hallmark of cancer, but their impact on the evolution and outcomes
of cancers is unknown. Here, we identified whole-genome doubling (WGD) in the tumors …

Mutations in BRCA1 and BRCA2 predispose individuals to certain cancers 1 , 2 – 3 , and
disease-specific screening and preventative strategies have reduced cancer mortality in …

PURPOSE Five percent to 9% of pancreatic ductal adenocarcinomas (PDACs) develop in
patients with a germline BRCA1/2 or PALB2 (gBRCA/PALB2+) mutation. Phase IB data from a …